2024 is set to be a watershed year for #Psychedelics. Alongside an influx of biotech investment in the UK, the industry has seen significant milestones set to accelerate the sector, return confidence & advance #MentalHealth innovations. Find out more. 👇 psychedelichealth.co.uk/2024/03/13/psy…

Could psilocybin offer a solution to the opioid crisis? We take a look in our latest blog post: filament.health/news/psychedel…

Today we announced that we have shipped our botanical psilocybin drug candidate, PEX010, to 4 countries for clinical trials at leading research institutions including Johns Hopkins University. filament.health/news/filament-…

We're proud to supply our botanical psilocybin for this important research at U Calgary:

The U Calgary is about to start a major study on psilocybin-assisted therapy for the treatment of alcoholism. British Columbia’s Filament Health will provide magic mushroom extract needed for the research. $FLHLF #psychedelics #psilocybin mugglehead.com/alberta-univer…

Read about U Calgary's upcoming study which will examine the effects of our botanical #psilocybin for alcohol use disorder:

Join Robert Sassoon for a fireside chat with Filament Health CEO Ben Lightburn on Thursday, April 4th, at 12:00 pm ET. #psychedelics #psychedelictherapy #therapeutics us06web.zoom.us/webinar/regist…

We're pleased to announce that Michael Messinger has been appointed to our Board of Directors, bringing over 20 years' experience in biotech finance roles. filament.health/news/filament-…

We're pleased to report our 2023 year-end results including $2.1 million in revenue + Health Canada and PHAC approval of a Filament-sponsored Phase 2 clinical trial studying our botanical psilocybin for opioid use disorder at University of British Columbia. filament.health/news/filament-…

Our CEO Ben Lightburn will be hosting an #AMA with CEO🔺CA at 12PM ET tomorrow to discuss our latest news and developments. Submit questions for Ben via: ceo.ca/@ceoca_james

We're pleased to report our Q1 2024 results, including important advancement of our drug development efforts in substance use disorders. filament.health/news/filament-…

Today we announced authorization by both U.S. FDA & Health Canada and PHAC of a Phase 2 clinical trial studying PEX010 for methamphetamine use disorder. This is the first ever clinical trial to study the safety & efficacy of botanical #psilocybin for MAUD. filament.health/news/filament-…

Today we announced a major expansion of our IP portfolio, with 12 new patents accepted in Australia, 5 in Canada, & 3 in the US. Filament holds a total of 46 allowed patents relating to the development & delivery of naturally-derived psychedelic APIs. filament.health/news/filament-…

We're proud to supply our botanical psilocybin drug candidate for this much-needed research into opioid use disorder at Imperial College London.

Today we announced the import of Peruvian coca leaf to our Vancouver R&D facility for the development of a botanical drug candidate to treat ADHD. filament.health/news/filament-…

.Ben Lightburn Filament Health discusses the company’s approach to psychedelic medicine, the case for natural botanical extracts rather than synthetic compounds, and its lead experimental therapy that targets methamphetamine use disorder. thebioreport.podbean.com/e/extracting-t…

Today we announced positive data from a phase 2 study of PEX010 in patients with alcohol use disorder. The study found that after 1 dose of #psilocybin, the mean % of heavy drinking days was reduced by more than 50% over the 12-week observation period. filament.health/news/filament-…

.Filament Health has received FDA approval for another clinical trial on its lead drug candidate PEX010. $FLHLF #psilocybin #Veterans #psychedelics mugglehead.com/fda-gives-anot…